Xbrane Raises Millions More As It Eyes Ranibizumab Filings
More Than 2.8 Million New Shares Issued
With ambitions to file biosimilar ranibizumab and initiate one new development program per year, Sweden’s Xbrane Biopharma has brought in millions of much needed fresh capital to fuel operations.
You may also be interested in...
Stada Generics Takes A Hit Even As Firm Steals A March On Rivals
Stada saw a small drop in both sales and profitability for its Generics division, but insisted the firm’s “strong position in generics,” alongside its leading position in consumer healthcare and growing specialty offering, “put the group on a sustainable growth course.”
Samsung Bioepis Backed By EMA For First Lucentis Biosimilar
Samsung Bioepis is set to make waves with the first ophthalmic biosimilar after the European regulator recommended that its ranibizumab biosimilar Byooviz receive a pan-European marketing authorization.
Xbrane Sets Cash Target Ahead Of Lucentis Ambitions In 2022
Swedish developer Xbrane Biopharma has identified a timeline to turn its cash flows positive, with plans to roll-out biosimilar Lucentis next year.